Refractoriness to anti‐ Helicobacter pylori treatment attributed to phenotypic resistance patterns in patients with gastroduodenopathy in Guayaquil‐Ecuador
Helicobacter · 2024
DOI: 10.1111/hel.13060 ↗Kurz gefasst
Fachartikel in der Zeitschrift Helicobacter, 2024. Verfasst von Javier David Lara Icaza und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centro Clínico Quirúrgico Ambulatorio (Hospital del Día) Efrén Jurado López, Guayaquil, Ecuador. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori, Anti-Infective Agents. Die Arbeit nennt 56 Literaturangaben.
Abstract (Originalsprache)
Background
Treatment of Helicobacter pylori gastric infection is complex and associated with increased rates of therapeutic failure. This research aimed to characterize the H . pylori infection status, strain resistance to antimicrobial agents, and the predominant lesion pattern in the gastroduodenal mucosa of patients with clinical suspicion of refractoriness to first‐ and second‐line treatment who were diagnosed and treated in a health center in Guayaquil, Ecuador.
Methods
A total of 374 patients with upper gastrointestinal symptoms and H . pylori infection were preselected and prescribed one of three triple therapy regimens for primary infection, as judged by the treating physician. Subsequently, 121 patients who returned to the follow‐up visit with persistent symptoms after treatment were studied.
Results
All patients had H . pylori infection. Histopathological examination diagnosed chronic active gastritis in 91.7% of cases; premalignant lesions were observed in 15.8%. The three triple therapy schemes applied showed suboptimal efficacy (between 47.6% and 77.2%), with the best performance corresponding to the scheme consisting of a proton pump inhibitor + amoxicillin + levofloxacin. Bacterial strains showed very high phenotypic resistance to all five antimicrobials tested: clarithromycin, 82.9%; metronidazole, 69.7%; amoxicillin and levofloxacin, almost 50%; tetracycline, 38.2%. Concurrent resistance to clarithromycin–amoxicillin was 43.4%, to tetracycline–metronidazole 30.3%, to amoxicillin–levofloxacin 27.6%, and to clarithromycin–metronidazole 59.2%.
Conclusions
In vitro testing revealed resistance to all five antibiotics, indicating that H . pylori exhibited resistance phenotypes to these antibiotics. Consequently, the effectiveness of triple treatments may be compromised, and further studies are needed to assess refractoriness in quadruple and concomitant therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centro Clínico Quirúrgico Ambulatorio (Hospital del Día) Efrén Jurado López, Guayaquil, Ecuador.
- Universidad del Zulia (LUZ), Maracaibo, Venezuela.
- Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador.
ORCID-Profile: Javier David Lara Icaza, Rosalina Lara Tapia, Cástula Tania Castro Triana, Laura Catalina Romero Ramírez
Zitieren
APA
Lara Icaza, J. D., Tapia, R. L., Triana, C. T. C., & Ramírez, L. C. R. (2024). Refractoriness to anti‐ Helicobacter pylori treatment attributed to phenotypic resistance patterns in patients with gastroduodenopathy in Guayaquil‐Ecuador. Helicobacter. https://doi.org/10.1111/hel.13060
Vancouver
Lara Icaza JD, Tapia RL, Triana CTC, Ramírez LCR. Refractoriness to anti‐ Helicobacter pylori treatment attributed to phenotypic resistance patterns in patients with gastroduodenopathy in Guayaquil‐Ecuador. Helicobacter. 2024. doi:10.1111/hel.13060
BibTeX
@article{LaraIcaza2024,
author = {Lara Icaza, Javier David and Tapia, Rosalina Lara and Triana, Cástula Tania Castro and Ramírez, Laura Catalina Romero},
title = {Refractoriness to anti‐ Helicobacter pylori treatment attributed to phenotypic resistance patterns in patients with gastroduodenopathy in Guayaquil‐Ecuador},
journal = {Helicobacter},
year = {2024},
doi = {10.1111/hel.13060}
}
EUVIMED